Announcements Trials

Browse Landscape

Phase

Phase 1/2 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Limited Stage Small Cell Lung Cancer 1 Head and Neck Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Hepatocellular 1 Alveolar Childhood Rhabdomyosarcoma 1

Interventions

Bevacizumab 69 Sorafenib 66 lenvatinib 59 durvalumab 38 sintilimab 33 Nivolumab 32 tislelizumab 28 atezolizumab 28 pembrolizumab 27 Oxaliplatin 26 tremelimumab 23 apatinib 22 Fluorouracil 22 Radiosurgery 20 regorafenib 19 camrelizumab 18 Doxorubicin 18 cabozantinib 16 Leucovorin 16 Capecitabine 16 Radiotherapy 14 Folfox protocol 14 donafenib 13 Gemcitabine 13 Cisplatin 12 toripalimab 11 Erlotinib Hydrochloride 10 spartalizumab 8 anlotinib 8 Neoadjuvant Therapy 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Hepatocellular × Tirapazamine × Clear all

NCT03145558 2024-11-22

TATE

Teclison Ltd.

Phase 2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡